Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30663033 | 0.98 | TSHR (0.50) | TSHRHIF1ACHRNA7HRH4HRH3 | |
| Bromide SCHEMBL20488683 | 0.95 | CHRNA7 (0.48) | TSHRHIF1ACHRNA7HRH4HRH3 | |
| Bromide SCHEMBL5618410 | 0.93 | CHRNA7 (0.49) | TSHRHIF1ACHRNA7HRH4HRH3 | |
| Bromide SCHEMBL20120670 | 0.93 | CHRNA7 (0.49) | TSHRHIF1ACHRNA7HRH4HRH3 | |
| Bromide SCHEMBL5359051 | 0.93 | CHRNA7 (0.49) | TSHRHIF1ACHRNA7HRH4HRH3 | |
| Bromide SCHEMBL2785247 | 0.93 | CHRNA7 (0.49) | TSHRHIF1ACHRNA7HRH4HRH3 | |
| Bromide SCHEMBL1244421 | 0.93 | CHRNA7 (0.49) | TSHRHIF1ACHRNA7HRH4HRH3 | |
| Bromide SCHEMBL1518997 | 0.93 | CHRNA7 (0.49) | TSHRHIF1ACHRNA7HRH4HRH3 | |
| Bromide SCHEMBL31020367 | 0.93 | CHRNA7 (0.49) | TSHRHIF1ACHRNA7HRH4HRH3 | |
| SCHEMBL31342768 | 0.91 | CHRNA7 (0.50) | TSHRHIF1ACHRNA7HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256757-B | Quaternary phosphonium salt composite antibacterial EVA (ethylene-vinyl acetate) insole material and preparation method thereof | 广州大学 | 2021-12-28 | — | — | CN | claimed |
| US-6248161-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT-PACKARD COMPANY | 2001-06-19 | — | — | US | claimed |
| WO-2026102147-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4652159-A1 | INHIBITORS OF KIF18A AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-11-26 | — | — | EP | disclosed |
| US-20250340569-A1 | INHIBITORS OF KIF18A AND USES THEREOF | INSILICO MEDICINE IP LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| WO-2025101588-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024238828-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024153217-A1 | INHIBITORS OF KIF18A AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-07-25 | — | — | WO | disclosed |
| WO-1999064379-A2 | BIOMIMETIC COMBINATORIAL SYNTHESIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0874826-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1998-11-04 | — | — | EP | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997024331-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-07-10 | — | — | WO | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-4097504-A | 11,12-Secoprostaglandins | MERCK & CO., INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4092356-A | 11,12-Secoprostaglandins | MERCK & CO., INC. (US) | 1978-05-30 | — | — | US | disclosed |
| US-4066692-A | 11,12-SECOPROSTAGLANDINS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340569-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF2C | TSHR 4396/4885HIF1A 4338/4885CHRNA7 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.